Tryptamine Therapeutics completes maiden dosing of IV psilocin – a global first
Tryptamine Therapeutics (ASX:TYP) has finished dosing the first patient with psilocin using an IV drip in a global first.
The Watchlist
Previous Video
Next Video
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
Previous Video
Next Video
SPONSORED BY The Market Online